The Zhitong Finance App learned that Giants Biotech (02367) fell 4% intraday, hitting a new low of HK$22.08 at the end of November 2022. As of press release, it decreased by 3.22% to HK$22.26, with a turnover of HK$129 million.

According to the news, Citi released a research report saying that the growth in online sales of cosmetics in China slowed in the third quarter of 2026 compared to the first half of the year, mainly dragged down by international brands, due to the low season after the 618 promotion, which is in line with the retail data trend of the National Bureau of Statistics. Within the scope of the bank, the Giants Biotech brand's online GMV is recovering from a low base, but the third season is not encouraging enough.

Also, on October 20, the new brand “1'me with me” under Giant Biotech debuted on Li Jiaqi's live broadcast. According to reports, 1'me is focusing on the internal and external linkage between skin care and oral nutrition, and has entered the market with rare ginsenosides as the core ingredient. It is worth noting that the two major brands, Kefumei and Clejin, have formed the basic market of Giuzi Biotech's skincare business. Together, the two account for more than 97% of the total revenue of the Group.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.